CERO THERAPEUTICS HOLDINGS, INC. (CERO) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US71902K4022

Price
0.01 USD
Market cap
416,548.71 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

CERO THERAPEUTICS HOLDINGS, INC. financials

Fiscal year2025
EBIT-19.92 m USD
Net income-19.92 m USD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About CERO THERAPEUTICS HOLDINGS, INC.

CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.